DEMEI FENG1,#, SHENRUI BAI1,#, GUANJUN CHEN1, BIBO FU1, CAILU SONG1, HAILIN TANG1, LIANG WANG2,*, HUA WANG1,*
Oncology Research, Vol.33, No.4, pp. 965-974, 2025, DOI:10.32604/or.2024.057065
- 19 March 2025
Abstract Objectives: The optimal treatment strategy for early-stage natural killer/T-cell lymphoma (NKTCL) remains unclear. This study aimed to evaluate and compare the clinical outcomes and adverse events (AEs) associated with two treatment regimens for early-stage NKTCL: pegaspargase with concurrent radiation therapy (P+CCRT) and pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) with sequential radiation therapy (SERT). Propensity score matching (PSM) was employed to ensure balanced comparison between these regimens. Methods: We assessed the efficacy of P+CCRT from a phase II trial and P-GEMOX combined with SERT using real-world data. PSM was conducted at a 1:1 ratio with a caliper… More >
Login
Register
